Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 40, 1852-1857, June 1, 1980]
© 1980 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gewirtz, D. A.
Right arrow Articles by Goldman, I. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gewirtz, D. A.
Right arrow Articles by Goldman, I. D.

Potent Bile Salt and Organic Anion Inhibition of Methotrexate Uptake and Accumulation in the Freshly Isolated Rat Hepatocyte1

David A. Gewirtz2, Joyce K. Randolph and I. David Goldman3

Department of Medicine, Medical College of Virginia, Richmond, Virginia 23298

Influx of [3H]methotrexate into freshly isolated hepatocytes is mediated by high- and low-affinity processes, both of which are inhibited by the bile salts, cholate, taurocholate, and deoxycholate, and the organic anions, bromosulfophthalein and rose bengal. At 100 µM concentrations, these compounds inhibit 1 µM [3H]methotrexate influx by 70 to 90%. Dixon plots established a similar Ki (~20 µM) for taurocholate inhibition of the high- and low-affinity influx routes for methotrexate, although the kinetics of this inhibition has not, as yet, been established. Bile salt inhibition of methotrexate influx requires the simultaneous presence of the bile salt and methotrexate at the cell membrane. Hence, pretreatment of hepatocytes with taurocholate, with subsequent removal of the bile salt from the extracellular compartment, does not alter methotrexate influx. Methotrexate at high concentration was found to inhibit the influx of [3H]taurocholate, suggesting the possibility of shared transport site(s) for bile salts and methotrexate. Influx of the naturally occurring folate, 5-methyltetrahydrofolate, is also inhibited by the bile salts and bromosulfophthalein, although to a lesser extent than influx of methotrexate. Cholate and taurocholate reduce not only methotrexate influx but also the net level of intracellular methotrexate accumulation, with a proportional reduction in the synthesis of methotrexate polyglutamate derivatives. Deoxycholate and bromosulfophthalein inhibit methotrexate polyglutamate synthesis to a greater extent than inhibition of total drug uptake. The presence of albumin in the buffer markedly reduces bromosulfophthalein inhibition of MTX influx, but has a much lesser effect on taurocholate inhibition of methotrexate influx, presumably related to the much higher affinity of albumin for bromosulfophthalein than for taurocholate.

These studies suggest that the level of bile salts in the hepatic sinusoids under physiological conditions may influence uptake and accumulation of methotrexate and its polyglutamate derivatives in hepatic parenchymal cells and may, therefore, influence the potential of this agent for producing hepatotoxicity in chemotherapeutic regimens. This raises the possibility that alterations in this interaction, in terms of regulation of bile salt pool size or time of administration of methotrexate relative to meals, may yield useful approaches for reducing methotrexate accumulation and metabolism in the liver and thereby minimize methotrexate hepatotoxicity especially in long-term low-dose regimens.

1 Supported by Grants CA-16906 and AM-18976 from the NIH.

2 Supported by Training Grant HL-07110 from the NIH.

3 To whom requests for reprints should be addressed.

Received 11/ 5/79. Accepted 2/19/80.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. J. Spinella, K. E. Brigle, E. E. Sierra, and I. D. Goldman
Distinguishing between Folate Receptor-alpha-mediated Transport and Reduced Folate Carrier-mediated Transport in L1210 Leukemia Cells
J. Biol. Chem., April 7, 1995; 270(14): 7842 - 7849.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.